#Group	GroupName	OddsRatio	FisherExactP	TargetGene:DrugNames
A00-A09	Intestinal infectious diseases	0.6060606060606061	0.810215055904713	PDE4A:drotaverine
A15-A19	Tuberculosis	0.0	1.0	
A20-A28	Certain zoonotic bacterial diseases	0.0	1.0	
A30-A49	Other bacterial diseases	0.0	1.0	
A50-A64	Infections with a predominantly sexual mode of transmission	0.0	1.0	
A65-A69	Other spirochaetal diseases	0.0	1.0	
A70-A74	Other diseases caused by chlamydiae	0.0	1.0	
A75-A79	Rickettsioses	0.0	1.0	
A80-A89	Viral infections of the central nervous system	0.0	1.0	
A92-A99	Arthropod-borne viral fevers and viral haemorrhagic fevers	0.0	1.0	
B00-B09	Viral infections characterized by skin and mucous membrane lesions	0.0	1.0	
B15-B19	Viral hepatitis	0.6980649872216137	0.7653438054311684	MMP9:rs-130830
B20-B24	Human immunodeficiency virus (HIV) disease	1.0608108108108107	0.5737939847881084	IL2RA:rft-5.dga	SIGMAR1:naltrexone
B25-B34	Other viral diseases	1.0920138888888888	0.5587796237280525	IL2RA:rft-5.dga	SIGMAR1:naltrexone
B35-B49	Mycoses	0.0	1.0	
B50-B64	Protozoal diseases	0.6566804407713499	0.7851686578359682	MMP9:curcumin
B65-B83	Helminthiases	0.0	1.0	
B85-B89	Pediculosis, acariasis and other infestations	0.0	1.0	
B90-B94	Sequelae of infectious and parasitic diseases	0.0	1.0	
B95-B98	Bacterial, viral and other infectious agents	0.0	1.0	
B99-B99	Other infectious diseases	0.0	1.0	
C00-C14	Malignant neoplasms of lip, oral cavity and pharynx	2.119311582726217	0.030626359421259478	IL15RA:alt-803	ICAM1:a-252444.0	ERBB3:mm-141,regn1400,drug 2849330,ktn3379,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,mehd7945a,anti-her3/egfr daf,av-203	C5:cgs-32359	PDE4A:pde4 inhibitors,ocid-2987	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:pnt-500,mgah22,zemab,hki-272,jnj-26483327,her2p63-71 peptide vaccine,tak-285,s-222611,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,zk 304709,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,ver-54505,r547,azd-5438	MMP9:cdp-845,dx-2802,curcumin,gs-5745,galarubicin	IL2RA:aldesleukin	DNMT1:xb-05,azacitidine,cp-4200,palifosfamide,rx-3117	CTLA4:ipilimumab,tremelimumab,del 60 tetramer
C15-C26	Malignant neoplasms of digestive organs	1.5262148337595909	0.17054233691861573	IL15RA:alt-803	ERBB3:mm-141,regn1400,drug 2849330,ktn3379,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,mehd7945a,anti-her3/egfr daf,av-203	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:mm-111,s-222611,trasgex,bms-599626,dn24-02,zemab,hki-272,tyverb/tykerb,recombinant human erbb3 fragment therapeutic tumor vaccine,pnt-500,mgah22,lapatinib,trastuzumab,arry-380,tak165,margetuximab,jnj-26483327,her2p63-71 peptide vaccine,tak-285,vm-206,hm-78136b,cipatinib,cudc-101	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,zk 304709,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,ver-54505,r547,azd-5438	MMP9:cdp-845,ct-1746,dx-2802,marimastat,gs-5745,curcumin,galarubicin	SIGMAR1:anavex 1007	IL2RA:aldesleukin	DNMT1:xb-05,azacitidine,cp-4200,palifosfamide,rx-3117	CTLA4:tremelimumab,del 60 tetramer
C30-C39	Malignant neoplasms of respiratory and intrathoracic organs	1.40625	0.23771274178978136	IL15RA:alt-803	ERBB3:mm-141,regn1400,drug 2849330,patritumab,ktn3379,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,amg888/u3-1287,mehd-7945a,soluble erbb3 theragnostics,mehd7945a,anti-her3/egfr daf,av-203	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:pnt-500,mgah22,zemab,hki-272,jnj-26483327,her2p63-71 peptide vaccine,tak-285,s-222611,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101,bibw 2992,dacomitinib	CDK2:sns-032,pha848125,pha-793887,pha-690509,seliciclib,at7519,ro 31-7453,inoc-005,zk 304709,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,bay 10-00394,ver-54505,r547,azd-5438	MMP9:cdp-845,neovastat,dx-2802,marimastat,gs-5745,curcumin,galarubicin	IL2RA:aldesleukin,denileukin diftitox	DNMT1:azacitidine,antroquinonol,cp-4200,palifosfamide,rx-3117,xb-05	CTLA4:ipilimumab,tremelimumab,del 60 tetramer
C40-C41	Malignant neoplasms of bone and articular cartilage	1.6257166257166258	0.14176432268806954	IL15RA:alt-803	ERBB3:mm-141,regn1400,drug 2849330,ktn3379,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,anti-her3/egfr daf,av-203	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:pnt-500,mgah22,zemab,hki-272,jnj-26483327,her2p63-71 peptide vaccine,tak-285,s-222611,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,zk 304709,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,ver-54505,r547,azd-5438	MMP9:cdp-845,dx-2802,curcumin,gs-5745,galarubicin	IL2RA:aldesleukin	DNMT1:xb-05,azacitidine,cp-4200,palifosfamide,rx-3117	CTLA4:tremelimumab,del 60 tetramer
C43-C44	Melanoma and other malignant neoplasms of skin	2.9745824255628177	0.001959369281396464	IL15RA:alt-803	ICAM1:a-252444.0	ERBB3:mm-141,regn1400,drug 2849330,ktn3379,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,anti-her3/egfr daf,av-203	C5:cgs-32359	PDE4A:pde4 inhibitors,ocid-2987	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:pnt-500,mgah22,zemab,hki-272,jnj-26483327,her2p63-71 peptide vaccine,tak-285,s-222611,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,tyverb/tykerb,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,zk 304709,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,ver-54505,r547,azd-5438	MMP9:cdp-845,dx-2802,curcumin,gs-5745,galarubicin	SIGMAR1:anavex 1007	IL2RA:aldesleukin	IL6R:sbp-002	DNMT1:xb-05,azacitidine,cp-4200,palifosfamide,rx-3117	CTLA4:ipilimumab,tremelimumab,del 60 tetramer	PMEL:imcgp100,multi-epitope tyrosinase/gp100 vaccine,melanoma vaccine,multi-epitope peptide melanoma vaccine,ae-08,gp100:209-217(210m) peptide vaccine
C45-C49	Malignant neoplasms of mesothelial and soft tissue	1.6058394160583942	0.1486238833602223	IL15RA:alt-803	ERBB3:mm-141,regn1400,drug 2849330,ktn3379,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,anti-her3/egfr daf,av-203	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:pnt-500,mgah22,zemab,hki-272,jnj-26483327,her2p63-71 peptide vaccine,tak-285,s-222611,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,zk 304709,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,ver-54505,r547,azd-5438	MMP9:cdp-845,dx-2802,curcumin,gs-5745,galarubicin	IL2RA:aldesleukin	DNMT1:xb-05,azacitidine,cp-4200,palifosfamide,rx-3117	CTLA4:ipilimumab,tremelimumab,del 60 tetramer
C50-C50	Malignant neoplasm of breast	2.0089628681177976	0.04553290387497716	IL15RA:alt-803	ERBB3:mm-141,mm-121,regn1400,drug 2849330,patritumab,ktn3379,ljm716,mp-rm-1,mm-151,recombinant human erbb3 fragment therapeutic tumor vaccine,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,anti-her3/egfr daf,av-203	PFKFB3:pfk-158	CSF3:spi-2012	ERBB2:her-2 protein autovac,mm-111,s-222611,bevacizumab + trastuzumab,pf-05280014,trasgex,bms-599626,dn24-02,zemab,mva her-2 autovac,hki-272,mm-302,tyverb/tykerb,varlitinib,recombinant human erbb3 fragment therapeutic tumor vaccine,her2/neu peptide vaccine,gw-974,ertumaxomab,avx901,pertuzumab,pnt-500,mgah22,taxol/paraplatin/herceptin,azd8931,lapatinib,neuvax,her-2-bi-armed atc,trastuzumab,arry-380,trastuzumab-dm1,tak165,anti-cd3 and anti-her2/neu bispecific antibody-armed activated t cells,jnj-26483327,her2p63-71 peptide vaccine,tak-285,vm-206,hm-78136b,pazopanib + tyverb/tykerb,cipatinib,cudc-101	CD40:hucd40l	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,zk 304709,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,ver-54505,r547,azd-5438	MMP9:cdp-845,dx-2802,curcumin,gs-5745,galarubicin	SIGMAR1:anavex 2-73	IL2RA:aldesleukin	DNMT1:xb-05,azacitidine,cp-4200,palifosfamide,rx-3117	CTLA4:ipilimumab,tremelimumab,del 60 tetramer
C51-C58	Malignant neoplasms of female genital organs	1.5164728682170543	0.18366123398296375	IL15RA:alt-803	ERBB3:mm-141,regn1400,drug 2849330,ktn3379,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,anti-her3/egfr daf,av-203	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:dn24-02,pnt-500,mgah22,zemab,hki-272,jnj-26483327,her2p63-71 peptide vaccine,tak-285,s-222611,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,zk 304709,r-roscovitine,ag-024322,cdk2 inhibitors,nu6140,sch-546909,tg02,ver-54505,r547,azd-5438	MMP9:cdp-845,dx-2802,curcumin,gs-5745,galarubicin	IL2RA:aldesleukin	DNMT1:xb-05,azacitidine,cp-4200,palifosfamide,rx-3117	CTLA4:tremelimumab,del 60 tetramer
C60-C63	Malignant neoplasms of male genital organs	1.922077922077922	0.05729504228730415	IL15RA:alt-803	ICAM1:apc-8015f	ERBB3:mm-141,regn1400,drug 2849330,ktn3379,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,anti-her3/egfr daf,av-203	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:dn24-02,pnt-500,mgah22,zemab,hki-272,jnj-26483327,her2p63-71 peptide vaccine,tak-285,s-222611,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,masoprocol,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101	CDK2:sns-032,pha-793887,pha-690509,seliciclib,at7519,ro 31-7453,inoc-005,zk 304709,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,ver-54505,r547,azd-5438	MMP9:cdp-845,dx-2802,curcumin,gs-5745,galarubicin	SIGMAR1:anavex 1007	IL2RA:aldesleukin	DNMT1:azacitidine,cp-4200,decitabine,palifosfamide,rx-3117,xb-05	CTLA4:ipilimumab,tremelimumab,del 60 tetramer
C64-C68	Malignant neoplasms of urinary tract	1.530054644808743	0.17786592302498205	IL15RA:alt-803	ERBB3:mm-141,regn1400,drug 2849330,ktn3379,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,anti-her3/egfr daf,av-203	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:dn24-02,pnt-500,mgah22,zemab,aby-025,hki-272,jnj-26483327,her2p63-71 peptide vaccine,tak-285,s-222611,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,zk 304709,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,ver-54505,r547,azd-5438	MMP9:cdp-845,neovastat,dx-2802,gs-5745,curcumin,galarubicin	IL2RA:aldesleukin	DNMT1:xb-05,azacitidine,cp-4200,palifosfamide,rx-3117	CTLA4:ipilimumab,tremelimumab,del 60 tetramer
C69-C72	Malignant neoplasms of eye, brain and other parts of central nervous system	1.5815304487179487	0.1574550063312531	IL15RA:alt-803	ERBB3:mm-141,regn1400,drug 2849330,ktn3379,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,anti-her3/egfr daf,av-203	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:pnt-500,mgah22,her2-targeted autologous t-cell therapy,zemab,hki-272,jnj-26483327,her2p63-71 peptide vaccine,tak-285,s-222611,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,zk 304709,pd-0183812,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,ver-54505,r547,azd-5438	MMP9:cdp-845,dx-2802,curcumin,gs-5745,galarubicin	IL2RA:aldesleukin	DNMT1:azacitidine,pmx-700,cp-4200,palifosfamide,rx-3117,xb-05	CTLA4:tremelimumab,del 60 tetramer
C73-C75	Malignant neoplasms of thyroid and other endocrine glands	1.6107723577235773	0.1468917872367707	IL15RA:alt-803	ERBB3:mm-141,regn1400,drug 2849330,ktn3379,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,anti-her3/egfr daf,av-203	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:pnt-500,mgah22,zemab,hki-272,jnj-26483327,her2p63-71 peptide vaccine,tak-285,s-222611,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,zk 304709,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,ver-54505,r547,azd-5438	MMP9:cdp-845,dx-2802,curcumin,gs-5745,galarubicin	IL2RA:aldesleukin	DNMT1:xb-05,azacitidine,cp-4200,palifosfamide,rx-3117	CTLA4:tremelimumab,del 60 tetramer
C76-C80	Malignant neoplasms of ill-defined, secondary and unspecified sites	1.7038690476190477	0.11769629073224305	IL15RA:alt-803	ERBB3:mm-141,regn1400,drug 2849330,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,av-203	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:pnt-500,mgah22,zemab,jnj-26483327,her2p63-71 peptide vaccine,tak-285,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,r-roscovitine,ag-024322,cdk2 inhibitors,sch-546909,tg02,ver-54505,azd-5438	MMP9:cdp-845,dx-2802,curcumin,gs-5745,galarubicin	IL2RA:aldesleukin	DNMT1:xb-05,azacitidine,cp-4200,palifosfamide	CTLA4:tremelimumab,del 60 tetramer
C81-C96	Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue	2.1544515494343335	0.023391326807064662	IL15RA:alt-803	ICAM1:bi-505,sar-1118	ERBB3:mm-141,regn1400,drug 2849330,mp-rm-1,recombinant human erbb3 fragment therapeutic tumor vaccine,mm-151,rg7116,sym-011,ezn-3920,gsk2849330,mehd-7945a,soluble erbb3 theragnostics,av-203	PDE4A:d-4418,theophylline,cd-160130	PFKFB3:pfk-158	CD40:hucd40l,apx-005	ERBB2:pnt-500,mgah22,zemab,ci-1033,jnj-26483327,her2p63-71 peptide vaccine,tak-285,vm-206,recombinant human erbb3 fragment therapeutic tumor vaccine,hm-78136b,trasgex,lapatinib,cp-724714,trastuzumab,arry-380,cipatinib,tak165,bms-599626,cudc-101,nelipepimut	RPL3:omacetaxine mepesuccinate	CDK2:sns-032,pha-793887,pha-690509,at7519,ro 31-7453,inoc-005,r-roscovitine,ag-024322,sch 727965,cdk2 inhibitors,rgb-286638,sch-546909,tg02,ver-54505,azd-5438	MMP9:cdp-845,neovastat,dx-2802,gs-5745,curcumin,galarubicin	IL2RA:aldesleukin,cht-25,lmb-2,denileukin diftitox	IL6R:fm-101,sant7	DNMT1:azacitidine,cp-4200,decitabine,s-110,palifosfamide,xb-05,sgi110	CTLA4:ipilimumab,tremelimumab,del 60 tetramer	RPS6KA2:bi-d1870
C97-C97	Malignant neoplasms of independent (primary) multiple sites	3.3042857142857143	0.0050863589339794745	ERBB3:rg7116,mehd-7945a,mm-151	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:cudc-101,mgah22,trastuzumab,bms-599626,hm-78136b	CDK2:ro 31-7453,sns-032,at7519,azd-5438	MMP9:gs-5745,galarubicin	IL2RA:aldesleukin	DNMT1:azacitidine,palifosfamide	CTLA4:tremelimumab
D00-D09	In situ neoplasms	2.934495412844037	0.009963156721602232	ERBB3:rg7116,mehd-7945a,mm-151	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:cudc-101,mgah22,trastuzumab,bms-599626,hm-78136b	CDK2:ro 31-7453,sns-032,at7519,azd-5438	MMP9:gs-5745,galarubicin	IL2RA:aldesleukin	DNMT1:azacitidine,palifosfamide	CTLA4:tremelimumab
D10-D36	Benign neoplasms	2.683220338983051	0.016145384194321225	ERBB3:rg7116,ktn3379,mehd-7945a,mm-151	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:cudc-101,mgah22,trastuzumab,bms-599626,hm-78136b	CDK2:ro 31-7453,sns-032,at7519,pha848125,azd-5438	MMP9:gs-5745,galarubicin	IL2RA:aldesleukin	DNMT1:azacitidine,palifosfamide,rx-3117	CTLA4:tremelimumab
D37-D48	Neoplasms of uncertain or unknown behaviour	2.84625	0.011775193012519813	ERBB3:rg7116,mehd-7945a,mm-151	PFKFB3:pfk-158	CD40:hucd40l	ERBB2:cudc-101,mgah22,trastuzumab,bms-599626,hm-78136b	CDK2:ro 31-7453,sns-032,at7519,azd-5438	MMP9:gs-5745,galarubicin	IL2RA:aldesleukin	DNMT1:azacitidine,cc-486,decitabine,oral azacitidine,palifosfamide,sgi110	CTLA4:tremelimumab
D50-D53	Nutritional anaemias	1.648989898989899	0.46790118087176136	PDE4A:theophylline
D55-D59	Haemolytic anaemias	1.696969696969697	0.4586661835004538	PDE4A:theophylline
D60-D64	Aplastic and other anaemias	3.4010416666666665	0.13186688646332134	PDE4A:theophylline	CSF3:interleukin-3
D65-D69	Coagulation defects, purpura and other haemorrhagic conditions	0.0	1.0	
D70-D77	Other diseases of blood and blood-forming organs	1.648989898989899	0.46790118087176136	CSF3:la-ep2006,neugranin,f-627,da-3031,mk-4214
D80-D89	Certain disorders involving the immune mechanism	7.558441558441558	0.00040148656515690695	ICAM1:inxc-icam1	PDE4A:zl-n-91	CD40:askp-1240	SIGMAR1:ssr-125329a	IL2RA:basiliximab	CD28:anti-cd28
E00-E07	Disorders of thyroid gland	0.0	1.0	
E10-E14	Diabetes mellitus	2.029334644378892	0.0863307214939378	C5:rev-576	PDE4A:ibudilast,pentoxifylline,dipyridamole	CD40:pg-120	IL2RA:humax-tac,basiliximab	IL6R:alx-0061,chu,ni-1201	CD28:fr-104,belatacept,tgn-1412	CTLA4:gx-c4
E15-E16	Other disorders of glucose regulation and pancreatic internal secretion	0.0	1.0	
E20-E35	Disorders of other endocrine glands	0.4383368569415081	0.896737130825566	BLK:compound 2
E40-E46	Malnutrition	0.0	1.0	
E50-E64	Other nutritional deficiencies	2.598155467720685	0.3349630854062415	PDE4A:al-59640
E65-E68	Obesity and other hyperalimentation	0.7160493827160493	0.7569263105467001	SIGMAR1:naltrexone
E70-E90	Metabolic disorders	0.3984526112185687	0.9169165834874504	PDGFB:cr-002
F00-F09	Organic, including symptomatic, mental disorders	0.8997668997668997	0.6781766539011705	PDE4A:ht-0712,denbufylline,gsk-356278
F10-F19	Mental and behavioural disorders due to psychoactive substance use	1.1480582524271845	0.5329803466637413	PDE4A:ibudilast	SIGMAR1:cm-156,naltrexone
F20-F29	Schizophrenia, schizotypal and delusional disorders	0.6809269162210339	0.7734780917779791	SIGMAR1:gevotroline,fh-510,sr-31742a,ms-377,panamesine,ne-100,npc-16377,e-6276,sa-5845,ssr-125047,bms-181100,cns-1307,cm-2395,dup-734,ne-033,rimcazole,cns-1169,e-5842
F30-F39	Mood [affective] disorders	0.8611111111111112	0.6810652344256534	PDE4A:mem-1414	SIGMAR1:igmesine,lu-29252,opc-14523,adx n05,cutamesine
F40-F48	Neurotic, stress-related and somatoform disorders	0.6893939393939394	0.7694457646146575	SIGMAR1:lu-29252
F50-F59	Behavioural syndromes associated with physiological disturbances and physical factors	0.7160493827160493	0.7569263105467001	SIGMAR1:opc-14523,adx n05
F60-F69	Disorders of adult personality and behaviour	0.0	1.0	
F70-F79	Mental retardation	0.0	1.0	
F80-F89	Disorders of psychological development	0.0	1.0	
F90-F98	Behavioural and emotional disorders with onset usually occurring in childhood and adolescence	0.0	1.0	
F99-F99	Unspecified mental disorder	0.0	1.0	
G00-G09	Inflammatory diseases of the central nervous system	1.34366391184573	0.5364753339010315	SIGMAR1:mc-116,sa-5845,mc-113
G10-G14	Systemic atrophies primarily affecting the central nervous system	2.0508474576271185	0.2724637956892565	PDE4A:gsk-356278	SIGMAR1:mc-116,sa-5845,mc-113
G20-G26	Extrapyramidal and movement disorders	1.1137971698113207	0.5485752898711953	PDE4A:ave-8112	SIGMAR1:mc-116,sa-5845,mc-113
G30-G32	Other degenerative diseases of the nervous system	0.3338809784592917	0.9474195541010462	SIGMAR1:anavex 2-73,anavex 1-41,mc-116,sa-5845,mc-113
G35-G37	Demyelinating diseases of the central nervous system	1.377000738734302	0.392042691246225	IL2RA:daclizumab	PDE4A:daxalipram	SIGMAR1:mc-116,sa-5845,mc-113
G40-G47	Episodic and paroxysmal disorders	0.8345323741007195	0.6967372797738085	SIGMAR1:adx n05,mc-116,sa-5845,mc-113	SLC12A5:clp-635
G50-G59	Nerve, nerve root and plexus disorders	1.5198135198135199	0.4946980337777854	SIGMAR1:mc-116,sa-5845,mc-113
G60-G64	Polyneuropathies and other disorders of the peripheral nervous system	0.5547648514851485	0.8713694480464829	PDE4A:ibudilast	SIGMAR1:oxycodex,avp-786,sa-5845,hydrocodex,pentazocine,mc-116,mc-113
G70-G73	Diseases of myoneural junction and muscle	1.481060606060606	0.503335674227932	SIGMAR1:mc-116,sa-5845,mc-113
G80-G83	Cerebral palsy and other paralytic syndromes	1.8016528925619835	0.43972718988388343	SIGMAR1:mc-116,sa-5845,mc-113
G90-G99	Other disorders of the nervous system	0.5457317073170732	0.8768442274386222	PDE4A:ibudilast	SIGMAR1:oxycodex,avp-786,sa-5845,hydrocodex,pentazocine,mc-116,mc-113
H00-H06	Disorders of eyelid, lacrimal system and orbit	0.0	1.0	
H10-H13	Disorders of conjunctiva	1.9198435972629522	0.42014574822823636	ICAM1:sar-1118
H15-H22	Disorders of sclera, cornea, iris and ciliary body	0.0	1.0	
H25-H28	Disorders of lens	0.0	1.0	
H30-H36	Disorders of choroid and retina	3.231924360400445	0.07999640995374084	C5:arc-1905,eculizumab,lfg-316	ERBB2:agn-208397	PDGFB:e-10030
H40-H42	Glaucoma	0.0	1.0	
H43-H45	Disorders of vitreous body and globe	0.0	1.0	
H46-H48	Disorders of optic nerve and visual pathways	0.0	1.0	
H49-H52	Disorders of ocular muscles, binocular movement, accommodation and refraction	0.0	1.0	
H53-H54	Visual disturbances and blindness	0.0	1.0	
H55-H59	Other disorders of eye and adnexa	1.8589015151515151	0.43001807900484373	SIGMAR1:dextromethorphan
H60-H62	Diseases of external ear	0.0	1.0	
H65-H75	Diseases of middle ear and mastoid	0.0	1.0	
H80-H83	Diseases of inner ear	0.0	1.0	
H90-H95	Other disorders of ear	0.0	1.0	
I00-I02	Acute rheumatic fever	1.6	0.3724803771295784	C5:pexelizumab	PDE4A:dipyridamole
I05-I09	Chronic rheumatic heart diseases	1.6	0.3724803771295784	C5:pexelizumab	PDE4A:dipyridamole
I10-I15	Hypertensive diseases	1.0256939234808702	0.5728856734292531	C5:pexelizumab	PDE4A:dipyridamole	S1PR2:edg5 antagonists
I20-I25	Ischaemic heart diseases	1.3527001862197392	0.3681773709758145	C5:pexelizumab	PDE4A:dipyridamole	SIGMAR1:dextromethorphan	SLC29A1:lidoflazine
I26-I28	Pulmonary heart disease and diseases of pulmonary circulation	1.102803738317757	0.5536968206127988	C5:pexelizumab	PDE4A:dipyridamole
I30-I52	Other forms of heart disease	0.9817985222562624	0.6006368829429432	C5:pexelizumab	PDE4A:dipyridamole	SLC12A5:bumetanide
I60-I69	Cerebrovascular diseases	1.282258064516129	0.4338099767052767	C5:pexelizumab	PDE4A:dipyridamole	MMP9:dp-b99
I70-I79	Diseases of arteries, arterioles and capillaries	0.7024539877300614	0.7783022973802283	C5:pexelizumab	PDE4A:pentoxifylline,dipyridamole,torbafylline
I80-I89	Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified	1.3548387096774193	0.401385765372737	C5:pexelizumab	PDE4A:dipyridamole	MMP9:dp-b99
I95-I99	Other and unspecified disorders of the circulatory system	0.9270833333333334	0.6435181187288432	C5:pexelizumab	PDE4A:dipyridamole
J00-J06	Acute upper respiratory infections	2.125	0.2598456440664442	PDE4A:cilomilast,asp-3258,tas-203,awd-12-281	SIGMAR1:dextromethorphan
J09-J18	Influenza and pneumonia	1.696969696969697	0.4586661835004538	PDE4A:cilomilast,asp-3258,tas-203
J20-J22	Other acute lower respiratory infections	2.598155467720685	0.3349630854062415	PDE4A:cilomilast,asp-3258,tas-203
J30-J39	Other diseases of upper respiratory tract	1.771139705882353	0.32909724432331877	PDE4A:cilomilast,asp-3258,tas-203,awd-12-281	SIGMAR1:dextromethorphan
J40-J47	Chronic lower respiratory diseases	1.2255855059655325	0.46116353133570914	C5:medi7814	PDE4A:roflumilast,tofimilast,ox-914,gsk256066,ci-1018,cilomilast,revamilast,sch-351591,chf-5480,theophylline,ic-485,dyphylline,asp-3258,tas-203,ronomilast,sotb07,cdp840,nik-616,gpd-1116,gw-3600,lirimilast,ch-3697,v-11294a,oglemilast,ono-6126,arofylline,pde4 inhibitors,ym-976,enprofylline,kw-4490	ERBB2:trastuzumab
J60-J70	Lung diseases due to external agents	3.7481060606060606	0.2505620822191769	PDE4A:cilomilast,asp-3258,tas-203
J80-J84	Other respiratory diseases principally affecting the interstitium	1.5198135198135199	0.4946980337777854	PDE4A:cilomilast,asp-3258,tas-203
J85-J86	Suppurative and necrotic conditions of lower respiratory tract	3.7481060606060606	0.2505620822191769	PDE4A:cilomilast,asp-3258,tas-203
J90-J94	Other diseases of pleura	3.7481060606060606	0.2505620822191769	PDE4A:cilomilast,asp-3258,tas-203
J95-J99	Other diseases of the respiratory system	2.992424242424242	0.2999861736811593	PDE4A:cilomilast,asp-3258,tas-203
K00-K14	Diseases of oral cavity, salivary glands and jaws	1.696969696969697	0.4586661835004538	TFF1:ag-013
K20-K31	Diseases of oesophagus, stomach and duodenum	1.2034632034632036	0.5748919370473924	SIGMAR1:kb-5492
K35-K38	Diseases of appendix	0.0	1.0	
K40-K46	Hernia	0.0	1.0	
K50-K52	Noninfective enteritis and colitis	2.2016129032258065	0.17638445061265082	PDE4A:cc-1088	MMP9:gs-5745	ICAM1:gi-270384x,alicaforsen
K55-K64	Other diseases of intestines	0.8856749311294766	0.6837507719702235	PDE4A:drotaverine
K65-K67	Diseases of peritoneum	0.0	1.0	
K70-K77	Diseases of liver	1.4988003199146893	0.3450124769781226	C5:cgs-32359	PDE4A:pde4 inhibitors,ocid-2987	ICAM1:a-252444.0
K80-K87	Disorders of gallbladder, biliary tract and pancreas	0.0	1.0	
K90-K93	Other diseases of the digestive system	2.7176308539944904	0.32349693170578425	ICAM1:isis 1570
L00-L08	Infections of the skin and subcutaneous tissue	4.8535980148883375	0.031619704315546816	STAT1:avt-02 ue	PDE4A:an-2898,e6005,roflumilast,gw842470x,ta-7906,crisaborole,kf-66490,an2728	SIGMAR1:pre-084
L10-L14	Bullous disorders	4.612116443745083	0.03566042865775324	STAT1:avt-02 ue	PDE4A:an-2898,e6005,roflumilast,gw842470x,ta-7906,crisaborole,kf-66490,an2728	SIGMAR1:pre-084
L20-L30	Dermatitis and eczema	3.2903225806451615	0.0769210236097467	STAT1:avt-02 ue	PDE4A:an-2898,e6005,roflumilast,gw842470x,ta-7906,crisaborole,kf-66490,an2728	SIGMAR1:pre-084,ssr-125329a
L40-L45	Papulosquamous disorders	4.58908507223114	0.004169849684728064	ICAM1:mor-102	ERBB3:elisidepsin	PDE4A:an-2898,e6005,roflumilast,capridine-beta,gw842470x,ta-7906,crisaborole,kf-66490,an2728,las-37779,apremilast,mk-0873	CDK2:capridine-beta	SIGMAR1:pre-084	STAT1:avt-02 ue
L50-L54	Urticaria and erythema	4.393098274568642	0.03995774907853672	STAT1:avt-02 ue	PDE4A:an-2898,e6005,roflumilast,gw842470x,ta-7906,crisaborole,kf-66490,an2728	SIGMAR1:pre-084
L55-L59	Radiation-related disorders of the skin and subcutaneous tissue	4.291055718475073	0.042201808658806336	STAT1:avt-02 ue	PDE4A:an-2898,e6005,roflumilast,gw842470x,ta-7906,crisaborole,kf-66490,an2728	SIGMAR1:pre-084
L60-L75	Disorders of skin appendages	2.6224443434802365	0.12459542632591702	STAT1:avt-02 ue	PDE4A:an-2898,e6005,roflumilast,gw842470x,ta-7906,crisaborole,kf-66490,an2728	SIGMAR1:pre-084
L80-L99	Other disorders of the skin and subcutaneous tissue	3.6666666666666665	0.033027278766279415	STAT1:avt-02 ue	PDE4A:an-2898,e6005,roflumilast,gw842470x,ta-7906,crisaborole,kf-66490,an2728	PDGFB:gam-501,pdgf-bb	SIGMAR1:pre-084
M00-M03	Infectious arthropathies	2.3296296296296295	0.11419330594190544	C5:cgs-32359	PDE4A:pde4 inhibitors,ocid-2987	ICAM1:a-252444.0	SIGMAR1:ssr-125329a
M05-M14	Inflammatory polyarthropathies	3.046658259773014	0.011297504961791105	ICAM1:a-252444.0	C5:nnc-0151-0000-0000,cgs-32359,mp-435	PDE4A:pde4 inhibitors,ocid-2987,piclamilast	CD40:anti-cd40-xten	MMP9:ro-319790	SIGMAR1:ssr-125329a	IL6R:sar153191,sa-237,tocilizumab,sarilumab,fezakinumabx	CTLA4:ctla-4-xten
M15-M19	Arthrosis	2.5148168103448274	0.06729159357113809	C5:cgs-32359	PDE4A:pde4 inhibitors,ocid-2987	MMP9:glucosamine	ICAM1:a-252444.0	SIGMAR1:ssr-125329a
M20-M25	Other joint disorders	2.3526479750778817	0.1114055432888795	C5:cgs-32359	PDE4A:pde4 inhibitors,ocid-2987	ICAM1:a-252444.0	SIGMAR1:ssr-125329a
M30-M36	Systemic connective tissue disorders	2.526666666666667	0.09281236595617384	IL6R:cnto-136	CXCR5:sar113244	SIGMAR1:igmesine,cutamesine	ICOS:medi-570
M40-M43	Deforming dorsopathies	0.0	1.0	
M45-M49	Spondylopathies	2.3823529411764706	0.22216356954286035	IL6R:sar153191	MMP9:glucosamine
M50-M54	Other dorsopathies	0.0	1.0	
M60-M63	Disorders of muscles	0.0	1.0	
M65-M68	Disorders of synovium and tendon	0.0	1.0	
M70-M79	Other soft tissue disorders	2.2948717948717947	0.36824123540154147	IL6R:chu
M80-M85	Disorders of bone density and structure	0.0	1.0	
M86-M90	Other osteopathies	0.0	1.0	
M91-M94	Chondropathies	0.0	1.0	
M95-M99	Other disorders of the musculoskeletal system and connective tissue	0.0	1.0	
N00-N08	Glomerular diseases	3.3074324324324325	0.13758704617056658	C5:sand-5	PDE4A:tjn-598,dipyridamole
N10-N16	Renal tubulo-interstitial diseases	1.8016528925619835	0.43972718988388343	PDE4A:dipyridamole
N17-N19	Renal failure	2.3353365384615383	0.22841411969238296	C5:sand-5	PDE4A:dipyridamole,tjn-598
N20-N23	Urolithiasis	1.8016528925619835	0.43972718988388343	PDE4A:dipyridamole
N25-N29	Other disorders of kidney and ureter	1.03125	0.5884543948632313	PDE4A:dipyridamole	BLK:compound 2
N30-N39	Other diseases of urinary system	0.0	1.0	
N40-N51	Diseases of male genital organs	0.0	1.0	
N60-N64	Disorders of breast	0.0	1.0	
N70-N77	Inflammatory diseases of female pelvic organs	0.0	1.0	
N80-N98	Noninflammatory disorders of female genital tract	0.0	1.0	
N99-N99	Other disorders of the genitourinary system	0.0	1.0	
O00-O08	Pregnancy with abortive outcome	0.0	1.0	
O10-O16	Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium	0.0	1.0	
O20-O29	Other maternal disorders predominantly related to pregnancy	0.0	1.0	
O30-O48	Maternal care related to the fetus and amniotic cavity and possible delivery problems	0.0	1.0	
O60-O75	Complications of labour and delivery	0.0	1.0	
O80-O84	Delivery	0.0	1.0	
O85-O92	Complications predominantly related to the puerperium	0.0	1.0	
O94-O99	Other obstetric conditions, not elsewhere classified	0.0	1.0	
P00-P04	Fetus and newborn affected by maternal factors and by complications of pregnancy, labour and delivery	nan	1.0	
P05-P08	Disorders related to length of gestation and fetal growth	0.0	1.0	
P10-P15	Birth trauma	0.0	1.0	
P20-P29	Respiratory and cardiovascular disorders specific to the perinatal period	0.0	1.0	
P35-P39	Infections specific to the perinatal period	0.0	1.0	
P50-P61	Haemorrhagic and haematological disorders of fetus and newborn	0.0	1.0	
P70-P74	Transitory endocrine and metabolic disorders specific to fetus and newborn	0.0	1.0	
P75-P78	Digestive system disorders of fetus and newborn	0.0	1.0	
P80-P83	Conditions involving the integument and temperature regulation of fetus and newborn	nan	1.0	
P90-P96	Other disorders originating in the perinatal period	0.0	1.0	
Q00-Q07	Congenital malformations of the nervous system	0.0	1.0	
Q10-Q18	Congenital malformations of eye, ear, face and neck	0.0	1.0	
Q20-Q28	Congenital malformations of the circulatory system	0.0	1.0	
Q30-Q34	Congenital malformations of the respiratory system	0.0	1.0	
Q35-Q37	Cleft lip and cleft palate	0.0	1.0	
Q38-Q45	Other congenital malformations of the digestive system	0.0	1.0	
Q50-Q56	Congenital malformations of genital organs	0.0	1.0	
Q60-Q64	Congenital malformations of the urinary system	0.0	1.0	
Q65-Q79	Congenital malformations and deformations of the musculoskeletal system	0.0	1.0	
Q80-Q89	Other congenital malformations	0.0	1.0	
Q90-Q99	Chromosomal abnormalities, not elsewhere classified	0.0	1.0	
R00-R09	Symptoms and signs involving the circulatory and respiratory systems	2.9786585365853657	0.16099608570022525	PDE4A:oxtriphylline	SIGMAR1:dextromethorphan polistirex,dextromethorphan
R10-R19	Symptoms and signs involving the digestive system and abdomen	1.1550802139037433	0.5893771367116258	PDE4A:theophylline
R20-R23	Symptoms and signs involving the skin and subcutaneous tissue	0.0	1.0	
R25-R29	Symptoms and signs involving the nervous and musculoskeletal systems	0.0	1.0	
R30-R39	Symptoms and signs involving the urinary system	1.2839262187088274	0.5522300771913203	SIGMAR1:ah-9700
R40-R46	Symptoms and signs involving cognition, perception, emotional state and behaviour	1.4441980783444197	0.5118299333200319	PDE4A:ht-0712,denbufylline
R47-R49	Symptoms and signs involving speech and voice	nan	1.0	
R50-R69	General symptoms and signs	0.6486486486486487	0.8353221981638865	ERBB2:bms-690514	SIGMAR1:oxycodex,avp-786,naltrexone,dextromethorphan,hydrocodex,pentazocine	SLC12A5:bumetanide
R70-R79	Abnormal findings on examination of blood, without diagnosis	0.0	1.0	
R80-R82	Abnormal findings on examination of urine, without diagnosis	0.0	1.0	
R83-R89	Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis	nan	1.0	
R90-R94	Abnormal findings on diagnostic imaging and in function studies, without diagnosis	nan	1.0	
R95-R99	Ill-defined and unknown causes of mortality	nan	1.0	
S00-S09	Injuries to the head	2.3878787878787877	0.3573322470851367	SIGMAR1:c-10068
S10-S19	Injuries to the neck	0.0	1.0	
S20-S29	Injuries to the thorax	0.0	1.0	
S30-S39	Injuries to the abdomen, lower back, lumbar spine and pelvis	0.0	1.0	
S40-S49	Injuries to the shoulder and upper arm	0.0	1.0	
S50-S59	Injuries to the elbow and forearm	0.0	1.0	
S60-S69	Injuries to the wrist and hand	0.0	1.0	
S70-S79	Injuries to the hip and thigh	0.0	1.0	
S80-S89	Injuries to the knee and lower leg	0.0	1.0	
S90-S99	Injuries to the ankle and foot	0.0	1.0	
T00-T07	Injuries involving multiple body regions	0.0	1.0	
T08-T14	Injuries to unspecified part of trunk, limb or body region	0.0	1.0	
T15-T19	Effects of foreign body entering through natural orifice	0.0	1.0	
T20-T25	Burns and corrosions of external body surface, specified by site	0.0	1.0	
T26-T28	Burns and corrosions confined to eye and internal organs	0.0	1.0	
T29-T32	Burns and corrosions of multiple and unspecified body regions	0.0	1.0	
T33-T35	Frostbite	0.0	1.0	
T36-T50	Poisoning by drugs, medicaments and biological substances	0.0	1.0	
T51-T65	Toxic effects of substances chiefly nonmedicinal as to source	0.0	1.0	
T66-T78	Other and unspecified effects of external causes	1.278225806451613	0.4785837968582036	PDE4A:d-22888,theophylline	ICAM1:sar-1118
T79-T79	Certain early complications of trauma	0.0	1.0	
T80-T88	Complications of surgical and medical care, not elsewhere classified	5.08235294117647	0.012252688921838919	IL2RA:basiliximab,inolimomab	ICAM1:inxc-icam1	CD28:belatacept	CD40:askp-1240
T90-T98	Sequelae of injuries, of poisoning and of other consequences of external causes	0.0	1.0	
U00-U49	Provisional assignment of new diseases of uncertain etiology or emergency use	nan	1.0	
U82-U85	Resistance to antimicrobial and antineoplastic drugs	nan	1.0	
V01-V09	Pedestrian injured in transport accident	nan	1.0	
V10-V19	Pedal cyclist injured in transport accident	nan	1.0	
V20-V29	Motorcycle rider injured in transport accident	nan	1.0	
V30-V39	Occupant of three-wheeled motor vehicle injured in transport accident	nan	1.0	
V40-V49	Car occupant injured in transport accident	nan	1.0	
V50-V59	Occupant of pick-up truck or van injured in transport accident	nan	1.0	
V60-V69	Occupant of heavy transport vehicle injured in transport accident	nan	1.0	
V70-V79	Bus occupant injured in transport accident	nan	1.0	
V80-V89	Other land transport accidents	nan	1.0	
V90-V94	Water transport accidents	nan	1.0	
V95-V97	Air and space transport accidents	nan	1.0	
V98-V99	Other and unspecified transport accidents	nan	1.0	
W00-W19	Falls	nan	1.0	
W20-W49	Exposure to inanimate mechanical forces	nan	1.0	
W50-W64	Exposure to animate mechanical forces	nan	1.0	
W65-W74	Accidental drowning and submersion	nan	1.0	
W75-W84	Other accidental threats to breathing	nan	1.0	
W85-W99	Exposure to electric current, radiation and extreme ambient air temperature and pressure	0.0	1.0	
X00-X09	Exposure to smoke, fire and flames	nan	1.0	
X10-X19	Contact with heat and hot substances	nan	1.0	
X20-X29	Contact with venomous animals and plants	nan	1.0	
X30-X39	Exposure to forces of nature	nan	1.0	
X40-X49	Accidental poisoning by and exposure to noxious substances	nan	1.0	
X50-X57	Overexertion, travel and privation	nan	1.0	
X58-X59	Accidental exposure to other and unspecified factors	nan	1.0	
X60-X84	Intentional self-harm	nan	1.0	
X85-Y09	Assault	nan	1.0	
Y10-Y34	Event of undetermined intent	nan	1.0	
Y35-Y36	Legal intervention and operations of war	nan	1.0	
Y40-Y59	Drugs, medicaments and biological substances causing adverse effects in therapeutic use	nan	1.0	
Y60-Y69	Misadventures to patients during surgical and medical care	nan	1.0	
Y70-Y82	Medical devices associated with adverse incidents in diagnostic and therapeutic use	nan	1.0	
Y83-Y84	Surgical and other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure	nan	1.0	
Y85-Y89	Sequelae of external causes of morbidity and mortality	nan	1.0	
Y90-Y98	Supplementary factors related to causes of morbidity and mortality classified elsewhere	nan	1.0	
Z00-Z13	Persons encountering health services for examination and investigation	0.0	1.0	
Z20-Z29	Persons with potential health hazards related to communicable diseases	0.0	1.0	
Z30-Z39	Persons encountering health services in circumstances related to reproduction	0.0	1.0	
Z40-Z54	Persons encountering health services for specific procedures and health care	0.0	1.0	
Z55-Z65	Persons with potential health hazards related to socioeconomic and psychosocial circumstances	0.0	1.0	
Z70-Z76	Persons encountering health services in other circumstances	0.0	1.0	
Z80-Z99	Persons with potential health hazards related to family and personal history and certain conditions influencing health status	0.0	1.0	
